National Brain Tumor Society’s
2016 Scientific Summit

District Hall, 75 Northern Avenue, Boston, MA
September 29, 2016, 8:30 AM – 5:00 PM


Leveraging the Inflection Point in Cancer Research to Advance Brain Tumor Treatments

This incredible, interactive day brings together renowned leaders from all aspects of the brain tumor field — many actively engaged in our ground-breaking research initiatives — to share progress, explore emerging opportunities, and build strong and diverse partnerships to fast-track new discoveries toward a cure.

The day features opportunities for robust and open dialog between participants and top experts from across the brain tumor community.

8:30 AM – 9:00 AM
Welcome & Keynote:
Outcomes of the Cancer Moonshot: Moving from Inflection to Further Progress  Dr. Elizabeth Jaffee (Cancer Moonshot Blue Ribbon Panel Co-Chair, Johns Hopkins University School of Medicine)

9:00 AM – 12:05 PM
NBTS Research Perspective:
COLLABORATION: What’s Working to Accelerate Progress and Capitalize on the Inflection Point in Cancer Research
(Q&A built in to individual time slots)
Together we will explore ways to overcome barriers; talk about successful, ongoing collaborative efforts; and learn more about exciting upcoming collaborations in the field, as well as how to optimize a “team science” approach to brain tumor research.

  • Defeat GBM: Progress


  • Project Impact: Defeat Pediatric Brain Tumors: Poised to Lift Off
  • Consortiums
  • The Importance of Patient Registries

12:15 PM – 1:15 PM
LUNCHTIME SESSION: Real World Evidence for Drug Development
This lunch session will highlight critical advances and opportunities as they apply to brain tumors, as well as how real-world patient data — gathered from health information technology platforms — can be used to augment knowledge about off-label use, conduct randomized trials, and collect data from patients who do not meet eligibility criteria for clinical trials to support regulatory decisions, such as the approval of new indications or label expansions for existing drugs.

1:20 PM – 3:25 PM
Innovation Today & Tomorrow: The Hot Topics/Emerging Opportunities in Brain Tumor Research
(Q&A built in)
Dr. Joohee Sul, FDA
Every day we are seeing exciting, new, innovative approaches emerging to combat the range of challenges we face in our field. Together we will explore a variety of forms this innovation is taking — including clinical trials, advancements in technology, cutting-edge areas of research, and new treatment protocols — and where it should go next according to the unique perspectives of our diverse participants.

  • Welcome and Intro
  • Advances in Treatment Development Landscape
  • Development of Imaging Biomarkers as Surrogate Endpoints
  • Liquid Biopsy for Brain Tumors
  • Epigenetics: A Rapidly Emerging Class of Therapeutic Targets for Brain Tumors (Pediatric & Adult)

3:35 PM – 4:50 PM
Panel & Open Discussion: What Progress Should we Demand to see in the Next 1-3 Years?
(Q&A built in to individual time slots)
This interactive session is set to discuss where we need to be heading next in adult and pediatric brain tumor research, patient engagement/patient role, treatment, policy, and advocacy. Join in the robust conversation from multiple perspectives regarding what needs to be leveraged or changed in order to make real progress in the fight against brain tumors and what we each have to do going forward.

  • Welcome Opening Statement and Key Questions for Discussion
  • Robust Panel and Audience Engagement
  • Summary and Wrap-up

4:50 PM – 5:00 PM
Closing Remarks


For more information contact Amanda Bates at or 516-632-8880.